Metaflammasome components in the human brain: a role in dementia with Alzheimer's pathology?

Brain Pathology

Volumn 27, Issue 3, 2017, Pages 266-275

  Taga, Mariko ^a,b   Minett, Thais ^c,d   Classey, John ^a   Matthews, Fiona E ^c   Brayne, Carol ^c   Ince, Paul G ^e   Nicoll, James A R ^a,f   Hugon, Jacques ^b,g,h   Boche, Delphine ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b University of Paris   (France)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Alzheimer's disease; CFAS; dementia; human brain; metaflammasome

Indexed keywords

APOLIPOPROTEIN E; I KAPPA B KINASE BETA; INFLAMMASOME; INSULIN RECEPTOR SUBSTRATE 1; METAFLAMMASOME; PROTEIN KINASE R; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; EIF2AK2 PROTEIN, HUMAN; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; CELL DENSITY; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MINI MENTAL STATE EXAMINATION; NEOCORTEX; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SENILE PLAQUE; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; MENTAL HEALTH; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PHOSPHORYLATION; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; EIF-2 KINASE; FEMALE; HUMANS; I-KAPPA B KINASE; IMMUNOHISTOCHEMISTRY; INSULIN RECEPTOR SUBSTRATE PROTEINS; MALE; MAP KINASE KINASE 4; MENTAL STATUS SCHEDULE; NEOCORTEX; PHOSPHORYLATION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84973541502     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12388     Document Type: Article

References (68)

1. Wimo A, Jonsson L, Bond J, Prince M, Winblad B (2013) The worldwide economic impact of dementia 2010. Alzheimers Dement 9:1–11 e3.
2. CFAS (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357:169–175.
3. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S et al (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73:768–774.
4. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362–381.
5. Raiha I, Kaprio J, Koskenvuo M, Rajala T, Sourander L (1996) Dementia in twins. Lancet 347:1706.
6. Bergem AL, Lannfelt L (1997) Apolipoprotein E type epsilon4 allele, heritability and age at onset in twins with Alzheimer disease and vascular dementia. Clinical Genetics 52:408–413.
7. Gatz M, Pedersen NL, Berg S, Johansson B, Johansson K, Mortimer JA et al (1997) Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol a Biol Sci Med Sci 52:M117–M125.
8. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90:1977–1981.
9. Bertram L (2011) Alzheimer's genetics in the GWAS era: a continuing story of 'replications and refutations'. Curr Neurol Neurosci Rep 11:246–253.
10. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41:1088–1093.
11. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41:1094–1099.
12. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D et al (2010) Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 5:e13950.
13. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635–641.
14. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61:661–666.
15. Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10:819–828.
16. Balakrishnan K, Verdile G, Mehta PD, Beilby J, Nolan D, Galvao DA et al (2005) Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis 8:269–282.
17. Duron E, Hanon O (2008) Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 4:363–381.
18. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA (2009) Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 28:75–80.
19. Akinyemi RO, Mukaetova-Ladinska EB, Attems J, Ihara M, Kalaria RN (2013) Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr Alzheimer Res 10:642–653.
20. Sato N, Morishita R (2013) Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front Aging Neurosci 5:64.
21. Wiesmann M, Kiliaan AJ, Claassen JA (2013) Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab 33:1696–1706.
22. Holmes C (2013) Systemic inflammation and Alzheimer's Disease. Neuropathol Appl Neurobiol 39:51–68.
23. Imai Y, Dobrian AD, Weaver JR, Butcher MJ, Cole BK, Galkina EV et al (2013) Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease. Diabetes Obes Metab 15(Suppl.3):117–129.
24. Jin C, Flavell RA (2013) Innate sensors of pathogen and stress: linking inflammation to obesity. J Allergy Clin Immunol 132:287–294.
25. Kang YS (2013) Obesity associated hypertension: new insights into mechanism. Electrolyte Blood Press 11:46–52.
26. Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426.
27. Guo H, Callaway JB, Ting JP (2015) Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 21:677–687.
28. Nakamura T, Furuhashi M, Li P, Cao H, Tuncman G, Sonenberg N et al (2010) Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 140:338–348.
29. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860–867.
30. Hotamisligil GS (2010) Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140:900–917.
31. Mouton-Liger F, Paquet C, Dumurgier J, Lapalus P, Gray F, Laplanche JL, Hugon J, Groupe d'Investigation du Liquide Cephalorachidien Study N (2012) Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease. Biol Psychiatry 71:829–835.
32. Gourmaud S, Paquet C, Dumurgier J, Pace C, Bouras C, Gray F et al (2015) Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. J Psychiatry Neurosci 40:151–161.
33. Brayne C, McCracken C, Matthews FE, Medical Research Council Coginitive F, Ageing S (2006) Cohort profile: the Medical Research Council Cognitive Function and Ageing Study (CFAS). Int J Epidemiol 35:1140–1145.
34. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, Medical Research Council Cognitive F, Ageing S (2009) Age, neuropathology, and dementia. N Engl J Med 360:2302–2309.
35. Gomez-Nicola D, Boche D (2015) Post-mortem analysis of neuroinflammatory changes in human Alzheimer's disease. Alzheimers Res Ther 7:42.
36. Bose A, Mouton-Liger F, Paquet C, Mazot P, Vigny M, Gray F, Hugon J (2011) Modulation of tau phosphorylation by the kinase PKR: Implications in Alzheimer's disease. Brain Pathol 21:189–200.
37. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A et al (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122:1316–1338.
38. Baeuerle PA (1991) The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim Biophys Acta 1072:63–80.
39. Coffey ET (2014) Nuclear and cytosolic JNK signalling in neurons. Nat Rev Neurosci 15:285–299.
40. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K (2005) Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330:1360.
41. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64:277–281.
42. Kennelly SP, Lawlor BA, Kenny RA (2009) Blood pressure and the risk for dementia: a double edged sword. Ageing Res Rev 8:61–70.
43. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ (2000) Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 21:49–55.
44. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L et al (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347:1141–1145.
45. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L (2003) Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 60:223–228.
46. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ (2003) Low blood pressure and the risk of dementia in very old individuals. Neurology 61:1667–1672.
47. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA (2001) Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 58:1640–6.
48. Ruitenberg A, Skoog I, Ott A, Aevarsson O, Witteman JC, Lernfelt B, et al, (2001) Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 12:33–39.
49. Nakatani Y, Kaneto H, Kawamori D, Hatazaki M, Miyatsuka T, Matsuoka TA, et al, (2004) Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 279:45803–45809.
50. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K et al (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333–336.
51. Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27:693–733.
52. Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MP (1995) Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci USA 92:9328–9332.
53. Mattson MP, Goodman Y, Luo H, Fu W, Furukawa K (1997) Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res 49:681–697.
54. Kaltschmidt B, Kaltschmidt C (2009) NF-kappaB in the nervous system. Cold Spring Harb Perspect Biol 1:a001271.
55. Arnold SE, Lucki I, Brookshire BR, Carlson GC, Browne CA, Kazi H et al (2014) High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol Dis 67:79–87.
56. Masliah E (1995) Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 10:509–519.
57. Garcia MA, Meurs EF, Esteban M (2007) The dsRNA protein kinase PKR: virus and cell control. Biochimie 89:799–811.
58. Dumurgier J, Mouton-Liger F, Lapalus P, Prevot M, Laplanche JL, Hugon J, Paquet C, Groupe d'Investigation du Liquide Cephalorachidien Study N (2013) Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease. PLoS One 8:e53587.
59. Damjanac M, Page G, Ragot S, Laborie G, Gil R, Hugon J, Paccalin M (2009) PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients. J Cell Mol Med 13:1823–1832.
60. Paquet C, Amin J, Mouton-Liger F, Nasser M, Love S, Gray F et al (2015) Effect of active Abeta immunotherapy on neurons in human Alzheimer's disease. J Pathol 235:721–730.
61. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B et al (2010) The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5:e9505.
62. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, et al, (2012) Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 9:151.
63. Weller RO, Preston SD, Subash M, Carare RO (2009) Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther 1:6.
64. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O et al (2011) APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16:903–907.
65. Liu ZG, Hsu H, Goeddel DV, Karin M (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87:565–576.
66. Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3:221–227.
67. Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G (2004) Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci 117:5197–5208.
68. Maeda S, Chang L, Li ZW, Luo JL, Leffert H, Karin M (2003) IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity 19:725–737.